The global Laband syndrome therapeutics market garnered a market value of USD 3 Billion in 2023 and is expected to accumulate a market value of USD 5 Billion by registering a CAGR of 5.2% in the forecast period 2023 to 2033. Laband syndrome, sometimes known as Zimmerman-Laband syndrome, is an exceedingly uncommon genetic illness marked by anomalies of the head and face, as well as the hands and feet. The majority of children with this condition have unusually big gums. Gum disease can impair your ability to chew, swallow, and/or talk.
Furthermore, afflicted newborns may have excessively long, thin fingers and toes, as well as malformed or missing nails at birth. Mental retardation may be present in some circumstances. Laband syndrome is thought to be inherited as an autosomal dominant characteristic in the majority of instances. This illness is known to be caused by disease-causing mutations in the following gene(s): ATP6V1B2, KCNN3, and KCNH1. This illness is believed to affect less than 1,000 people in the United States.
The Laband syndrome therapeutics market is expected to increase significantly throughout the projected period of 2023 to 2033, owing to the increasing incidence of genetic illnesses worldwide. The rising prevalence of genetic illnesses, as well as the growing need to cure them at an early stage, have broadened the scope of diagnostic developments. As a result, the genetic Laband syndrome therapeutics market will see huge growth prospects.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 3 Billion |
| Anticipated Forecast Value (2033) | USD 5 Billion |
| Projected Growth Rate (2023 to 2033) | 5.2% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for Laband syndrome therapeutics is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of USD 5 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4%.
The rising frequency of rare diseases as a result of changing lifestyles and an increase in pediatric disorders is driving the expansion of the laband syndrome therapeutics market. Furthermore, the surging prevalence of genetic illnesses such as ATP6V1B2, KCNN3, and KCNH1, as well as improved success rates of stem cell transplantation, may be driving forces in the industry.
Rising Prevalence of Genetic Disorders to Improve Maintenance and Performance
The increasing prevalence of genetic disorders throughout the world, as well as the necessity for testing to successfully treat the problem, may fuel the expansion of the market. The worldwide population is becoming more aware of genetic abnormalities and the medicines accessible for treatment processes.
Prenatal operations have gained popularity because they improve the lives of patients. Furthermore, attempts to make diagnostics simpler and less expensive may open up new avenues for the expansion of the Laband syndrome therapeutics industry.
Principal Consultant
The efforts of research and development have aided in the creation of new and creative treatments such as robotic radiosurgery, SBRT, and the use of molecular target agents, which may bring value to the market.
The expansion of the market has been impacted by advancements in healthcare processes along with well-equipped infrastructure. Furthermore, the increased interest of healthcare professionals in generic illnesses is expected to give profitable prospects for the market to expand.
Complications of Therapies to Hamper Market Growth
Therapy can make mistakes, and additional genes introduced during the operation might become intruders, affecting the immune system. The misdirection of the gene, which has a detrimental influence on the cell, as well as the high cost of the medicines, is restraining the laband syndrome therapeutics industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Rising Healthcare Expenditure for Widening Profit Margins
Over the projection period, the Asia Pacific regional market is predicted to increase at a rapid pace. The constant development of the medical tourism industry, rising healthcare expenditure, and growing government initiatives pertaining to the development of healthcare infrastructure, primarily biotechnology, agriculture, and pharmacology, are just a few of the factors contributing to the rapid growth of the Asia Pacific Laband syndrome therapeutics market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 4.8% in the assessment period 2023-2033.
Presence of Established Healthcare Infrastructure in the Region to Accelerate Market Growth
The bulk of the worldwide Laband syndrome therapeutics market share was governed by North America. The presence of established healthcare infrastructure in the region, the availability of qualified specialists and advanced genetic testing equipment, high healthcare spending, and superior reimbursement rules are key reasons contributing to its substantial share. North America is expected to grow at a CAGR of 5.1% in the assessment period 2023-2033.
Availability of Competent Personnel and Diagnostic Equipment fuelling sales of the Market
Because of the availability of competent personnel and diagnostic equipment, Europe may see significant development. As a result, the global laband syndrome therapeutics market may experience substantial expansion. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 5% in the assessment period 2023-2033.
The Bisphosphonates Segment to enhance Sales Prospects
The frequency and prevalence of bone disorders drive the bisphosphonates segment. The growing elderly population is the primary driver of the bisphosphonates segment. As people age, their bone density decreases, and they are more likely to fracture, therefore bisphosphonate medication becomes important for them.
According to a 2013 The USA Department of Health and Human Services survey, almost 14.1% of the USA population was over the age of 65, and this number is fast growing. Another important factor supporting the growth of the bisphosphonates segment is the increase in the number of postmenopausal women suffering from bone thinning.
The Oral Segment is expected to Drive the Market
The growing number of drug pipelines will have a favorable influence on the oral route of the administration segment throughout the forecast period.
The Drug Store Segment to Rule over the Market
The drug stores business is projected to be driven by the world's aging population and rising health consciousness. The older population is more susceptible to contracting various ailments, which increases their reliance on drug stores, thereby influencing the market.
Key Start-up players in the laband syndrome therapeutics are offering new and innovative product lines to consolidate their market presence, these aforementioned Start-ups have left no stone unturned. Some specific instances of key laband syndrome therapeutics Start-ups are as follows:
Scenic Biotech, an Israeli firm, finds genetic modifiers. Cell-Seq, the company's proprietary genomics platform, seeks disease suppressors or genes that counterbalance the action of a disease-causing gene. Cell-Seq employs unique human cells that have just one copy of each gene (haploid), rather than the typical two (diploid). The company detects and chooses genes that prevent illness inheritance among descendants. Scenic Biotech builds a library of mutated cells and uses bioinformatics analysis to designate the modifiers against the illnesses they prevent. The firm empowers pharmacists and scientists to create treatments for life-threatening disorders such as hereditary rare diseases and cancer.
e-Zyvec, a French firm, provides personalized DNA vectors. The company focuses on genetic engineering for biopharmaceutical manufacturing. It offers gene editing and modification to introduce genes of interest or to eliminate one or more genetic functions for gene therapy and cell therapy applications. Researchers may use the startup to interpret and study disease-causing genes and modifiers, as well as their influence on illnesses.
Genome Medical, situated in the United States, allows virtual genetic care and educated healthcare decisions. It makes AI-powered suggestions for illness testing and patient evaluation. The platform combines and analyses diagnostic test findings in the context of demographic and family history data from patients. It forecasts the risk of cancer, heart disease, and other inherited illnesses. This enables physicians and patients to create care pathways and customize therapy. Furthermore, the startup provides clinical assistance for tailored care and treatment through resources, education, and peer consultation.
Key players in the laband syndrome therapeutics market are Xinhua Pharmaceutical, BASF, SI Group, Strides Pharma Science, Selleckchem, Merck & Co. Inc., Vasudha Pharma Chem Limited, Sanofi, Takeda, and Pfizer.
Recent Developments:
In December 2022 - BASF Pharma Solutions announced that the FDA's Center for Drug Evaluation and Research (CDER), Office of New Drugs has accepted their excipient, Soluplus®, into the FDA's Pilot Program for the Review of Innovation and Modernization of Excipients (PRIME). The program aims to reduce the risk and burden on pharmaceutical companies that want to use novel excipients for modern drug development challenges, as well as to provide a pathway for excipient manufacturers like BASF to obtain an FDA review of their novel excipients before using them in an FDA-approved drug.
In December 2022 - telis Biopharma Limited, an emerging biopharmaceutical Contract Development and Manufacturing Organization (CDMO) and the biologics arm of Strides Pharma Science Limited, announced that its CDMO partner has received FDA approval for a key ANDA (USFDA). The product was filed from Stelis Biopharma's flagship facility in Bangalore.
In December 2022 Merck inked a non-binding Memorandum of Understanding (MoU) with Synplogen, a business spun out of Kobe University's Graduate School of Science, Technology, and Innovation. Both businesses want to combine their resources in order to provide expedited development, production, and testing for viral vector gene treatments in Japan.
In December 2022 Sanofi and Innate Pharma SA announced an extension of their relationship, with Sanofi licensing an ANKETTM platform natural killer (NK) cell engager program targeting B7H3. Sanofi will also be able to add up to two more ANKETTM targets. Sanofi will be in charge of all development, production, and marketing when the candidate is chosen. In 2016, Innate and Sanofi formed their first NK cell engagers agreement for the creation and study of up to two bispecific NK cell engagers, which are now being investigated by Sanofi's Research and Development (R&D) team, with one of these compounds already in clinical trials.
In July 2022 - SI Group, a major worldwide performance additives firm, completed the sale of its 81-acre headquarters site at 2750 Balltown Road in Niskayuna to Momentive Performance Materials Group (Momentive). SI Group will keep a presence in the Capital Region by building a new office in Schenectady's Mohawk Harbor, while relocating its worldwide headquarters and research and development facilities to Texas.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3 Billion |
| Market Value in 2033 | USD 5 Billion |
| Growth Rate | CAGR of 5.2% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in the USA Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Xinhua Pharmaceutical; BASF; SI Group; Strides Pharma Science; Selleckchem; Merck & Co. Inc.; Vasudha Pharma Chem Limited; Sanofi; Takeda; Pfizer |
| Customization | Available Upon Request |
From 2018 to 2022, the global market exhibited a CAGR of 4%.
The market is forecast to register a CAGR of 5.2% through 2033.
The rising prevalence of genetic disorders improves maintenance and performance.
North America is likely to develop at a CAGR of 5.1% through 2033.
Europe is expected to develop at a CAGR of 5% from 2023 to 2033.
1. Executive Summary | Laband Syndrome Therapeutics Market 2. Market Overview 3. Market Background 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. NSAIDS 5.2. Bisphosphonate 5.3. Skeletal Muscle Relaxants 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Rectal 6.3. Parental 6.4. Topical 6.5. Infusion 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Clinical Pharmacies 7.3. Drug Stores 7.4. Online Pharmacies 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa (MEA) 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Xinhua Pharmaceutical 16.2. BASF 16.3. SI Group 16.4. Strides Pharma Science 16.5. Selleckchem 16.6. Merck & Co. Inc. 16.7. Vasudha Pharma Chem Limited 16.8. Sanofi 16.9. Takeda 16.10. Pfizer 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Laband Syndrome Therapeutics Market
